1
|
Mangeat T, Gracia M, Pichard A, Poty S, Martineau P, Robert B, Deshayes E. Fc-engineered monoclonal antibodies to reduce off-target liver uptake. EJNMMI Res 2023; 13:81. [PMID: 37697076 PMCID: PMC10495296 DOI: 10.1186/s13550-023-01030-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/17/2023] [Accepted: 08/28/2023] [Indexed: 09/13/2023] Open
Abstract
BACKGROUND Radiolabeled-antibodies usually display non-specific liver accumulation that may impair image analysis and antibody biodistribution. Here, we investigated whether Fc silencing influenced antibody biodistribution. We compared recombinant 89Zr-labeled antibodies (human IgG1 against different targets) with wild-type Fc and with mutated Fc (LALAPG triple mutation to prevent binding to Fc gamma receptors; FcγR). After antibody injection in mice harboring xenografts of different tumor cell lines or of immortalized human myoblasts, we analyzed antibody biodistribution by PET-CT and conventional biodistribution analysis. RESULTS Accumulation in liver was strongly reduced and tumor-specific targeting was increased for the antibodies with mutated Fc compared with wild-type Fc. CONCLUSION Antibodies with reduced binding to FcγR display lower liver accumulation and better tumor-to-liver ratios. These findings need to be taken into account to improve antibody-based theragnostic approaches.
Collapse
Affiliation(s)
- Tristan Mangeat
- Institut de Recherche en Cancérologie de Montpellier (IRCM), Inserm U1194, Université de Montpellier, ICM, 34298, Montpellier, France
| | - Matthieu Gracia
- Institut de Recherche en Cancérologie de Montpellier (IRCM), Inserm U1194, Université de Montpellier, ICM, 34298, Montpellier, France
| | - Alexandre Pichard
- Institut de Recherche en Cancérologie de Montpellier (IRCM), Inserm U1194, Université de Montpellier, ICM, 34298, Montpellier, France
| | - Sophie Poty
- Institut de Recherche en Cancérologie de Montpellier (IRCM), Inserm U1194, Université de Montpellier, ICM, 34298, Montpellier, France
| | - Pierre Martineau
- Institut de Recherche en Cancérologie de Montpellier (IRCM), Inserm U1194, Université de Montpellier, ICM, 34298, Montpellier, France
| | - Bruno Robert
- Institut de Recherche en Cancérologie de Montpellier (IRCM), Inserm U1194, Université de Montpellier, ICM, 34298, Montpellier, France.
- Institut de Recherche en Cancérologie de Montpellier (IRCM), 124 Avenue des Apothicaires, 34090, Montpellier, France.
| | - Emmanuel Deshayes
- Institut de Recherche en Cancérologie de Montpellier (IRCM), Inserm U1194, Université de Montpellier, ICM, 34298, Montpellier, France.
- Institut Régional du Cancer de Montpellier (ICM), Service de Médecine Nucléaire, 34298, Montpellier, France.
- Institut de Recherche en Cancérologie de Montpellier (IRCM), 124 Avenue des Apothicaires, 34090, Montpellier, France.
| |
Collapse
|
2
|
Karam J, Constanzo J, Pichard A, Gros L, Chopineau J, Morille M, Pouget JP. Rapid communication: insights into the role of extracellular vesicles during Auger radioimmunotherapy. Int J Radiat Biol 2023; 99:109-118. [PMID: 34270378 DOI: 10.1080/09553002.2021.1955999] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
Abstract
PURPOSE Non-targeted effects, including bystander and systemic effects, play a crucial role during Auger targeted radionuclide therapy. Here, we investigated whether small extracellular vesicles (sEVs) produced by irradiated cells could contribute to the bystander cytotoxic effects in vitro and also to therapeutic efficacy in vivo, after their injection in tumor xenografts. MATERIALS AND METHODS B16F10 melanoma donor cells were exposed to radiolabeled antibodies (Auger radioimmunotherapy, RIT) for 48 h or to X-rays (donor cells). Then, donor cells were incubated with fresh medium for 2 h to prepare conditioned medium (CM) that was transferred onto recipient cells for bystander effect assessment, or used for sEVs enrichment. Resulting sEVs were incubated in vitro with recipient cells for determining bystander cytotoxicity, or injected in B16F10 melanoma tumors harbored by athymic and C57BL/6 mice. RESULTS In vitro analysis of bystander cytotoxic effects showed that CM killed about 30-40% of melanoma cells. SEVs isolated from CM contributed to this effect. Moreover, the double-stranded DNA (dsDNA) content was increased in sEVs isolated from CM of exposed cells compared to control (not exposed), but the difference was significant only for the X-ray condition. These results were supported by immunodetection of cytosolic dsDNA in donor cells, a phenomenon that should precede dsDNA enrichment in sEVs. However, sEVs cytotoxicity could not be detected in vivo. Indeed, in athymic and in immunocompetent mice that received four intratumoral injections of sEVs (1/day), tumor growth was not delayed compared with untreated controls. Tumor growth was slightly (not significantly) delayed in immunocompetent mice treated with sEVs from X-ray-exposed cells, and significantly with sEVs purified from CM collected after 48 h of incubation. These results highlight the need to determine the optimal conditions, including radiation absorbed dose and sEVs collection time, to obtain the strongest cytotoxic effects. CONCLUSIONS This study demonstrates that sEVs could play a role during Auger RIT through bystander effects in vitro. No systemic effects were observed in vivo, under our experimental conditions. However, X-rays experiments showed that sEVs collection time might be influencing the nature of sEVs, a parameter that should also be investigated during Auger RIT.
Collapse
Affiliation(s)
- Jihad Karam
- Institut de Recherche en Cancérologie de Montpellier (IRCM), Inserm U1194, Institut Régional du Cancer de Montpellier (ICM), Université de Montpellier, Montpellier, France
| | - Julie Constanzo
- Institut de Recherche en Cancérologie de Montpellier (IRCM), Inserm U1194, Institut Régional du Cancer de Montpellier (ICM), Université de Montpellier, Montpellier, France
| | - Alexandre Pichard
- Institut de Recherche en Cancérologie de Montpellier (IRCM), Inserm U1194, Institut Régional du Cancer de Montpellier (ICM), Université de Montpellier, Montpellier, France
| | - Laurent Gros
- Institut de Recherche en Cancérologie de Montpellier (IRCM), Inserm U1194, Institut Régional du Cancer de Montpellier (ICM), Université de Montpellier, Montpellier, France
| | - Joël Chopineau
- ICGM, ENSCM, CNRS, Université de Montpellier, Montpellier, France
| | - Marie Morille
- ICGM, ENSCM, CNRS, Université de Montpellier, Montpellier, France
| | - Jean-Pierre Pouget
- Institut de Recherche en Cancérologie de Montpellier (IRCM), Inserm U1194, Institut Régional du Cancer de Montpellier (ICM), Université de Montpellier, Montpellier, France
| |
Collapse
|
3
|
Pouget JP, Santoro L, Piron B, Paillas S, Ladjohounlou R, Pichard A, Poty S, Deshayes E, Constanzo J, Bardiès M. From the target cell theory to a more integrated view of radiobiology in Targeted radionuclide therapy: The Montpellier group's experience. Nucl Med Biol 2021; 104-105:53-64. [PMID: 34922279 DOI: 10.1016/j.nucmedbio.2021.11.005] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/17/2021] [Revised: 07/12/2021] [Accepted: 11/25/2021] [Indexed: 11/24/2022]
Abstract
Targeted radionuclide therapy (TRT) is used to treat disseminated or metastatic tumours in which conventional external beam radiotherapy (EBRT) would have unacceptable side effects. Unlike EBRT, TRT delivers low doses at a continuous low dose rate. In EBRT, the effect increases progressively with the dose rate, and biological effects (tumour control and normal tissue damage) are related to the dose according to a sigmoid curve model. This model is part of the so-called quantitative radiobiology that is mostly based on the target cell theory, according to which cell death is due to (lethal) radiation hits to vital cellular targets. This model was developed for EBRT, but was adapted to low dose-rate situations by including a parameter that reflects the time needed to repair tissue damage. However, a growing body of evidence indicates that the model should take into account also the biological effects, which are due to intercellular communications (bystander effects) and amplify the effects of radiation, as well as the immune system. Moreover, extranuclear targets must be considered, although induced intracellular and intercellular signalling pathways may ultimately result in DNA damage. It is likely that bystander effects and immune response always contribute to the overall response to TRT at different levels, and that dose and dose rate are key parameters in controlling their real contribution. We hypothesize that the dose rate is the key determinant in the balance between the physical and DNA-centred response on one side, and the biological response that integrates all subcellular compartments and intercellular signalling pathways on the other side.
Collapse
Affiliation(s)
- Jean-Pierre Pouget
- Institut de Recherche en Cancérologie de Montpellier (IRCM), Inserm U1194, Université de Montpellier, Institut Régional du Cancer de Montpellier (ICM), Montpellier F-34298, France.
| | - Lore Santoro
- Institut de Recherche en Cancérologie de Montpellier (IRCM), Inserm U1194, Université de Montpellier, Institut Régional du Cancer de Montpellier (ICM), Montpellier F-34298, France
| | - Bérengère Piron
- Institut de Recherche en Cancérologie de Montpellier (IRCM), Inserm U1194, Université de Montpellier, Institut Régional du Cancer de Montpellier (ICM), Montpellier F-34298, France
| | - Salomé Paillas
- Institut de Recherche en Cancérologie de Montpellier (IRCM), Inserm U1194, Université de Montpellier, Institut Régional du Cancer de Montpellier (ICM), Montpellier F-34298, France
| | - Riad Ladjohounlou
- Institut de Recherche en Cancérologie de Montpellier (IRCM), Inserm U1194, Université de Montpellier, Institut Régional du Cancer de Montpellier (ICM), Montpellier F-34298, France
| | - Alexandre Pichard
- Institut de Recherche en Cancérologie de Montpellier (IRCM), Inserm U1194, Université de Montpellier, Institut Régional du Cancer de Montpellier (ICM), Montpellier F-34298, France
| | - Sophie Poty
- Institut de Recherche en Cancérologie de Montpellier (IRCM), Inserm U1194, Université de Montpellier, Institut Régional du Cancer de Montpellier (ICM), Montpellier F-34298, France
| | - Emmanuel Deshayes
- Institut de Recherche en Cancérologie de Montpellier (IRCM), Inserm U1194, Université de Montpellier, Institut Régional du Cancer de Montpellier (ICM), Montpellier F-34298, France
| | - Julie Constanzo
- Institut de Recherche en Cancérologie de Montpellier (IRCM), Inserm U1194, Université de Montpellier, Institut Régional du Cancer de Montpellier (ICM), Montpellier F-34298, France
| | - Manuel Bardiès
- Institut de Recherche en Cancérologie de Montpellier (IRCM), Inserm U1194, Université de Montpellier, Institut Régional du Cancer de Montpellier (ICM), Montpellier F-34298, France
| |
Collapse
|
4
|
Idrissou MB, Pichard A, Tee B, Kibedi T, Poty S, Pouget JP. Targeted Radionuclide Therapy Using Auger Electron Emitters: The Quest for the Right Vector and the Right Radionuclide. Pharmaceutics 2021; 13:pharmaceutics13070980. [PMID: 34209637 PMCID: PMC8309076 DOI: 10.3390/pharmaceutics13070980] [Citation(s) in RCA: 11] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/22/2021] [Revised: 06/20/2021] [Accepted: 06/24/2021] [Indexed: 12/25/2022] Open
Abstract
Auger electron emitters (AEEs) are attractive tools in targeted radionuclide therapy to specifically irradiate tumour cells while sparing healthy tissues. However, because of their short range, AEEs need to be brought close to sensitive targets, particularly nuclear DNA, and to a lower extent, cell membrane. Therefore, radioimmunoconjugates (RIC) have been developed for specific tumour cell targeting and transportation to the nucleus. Herein, we assessed, in A-431CEA-luc and SK-OV-31B9 cancer cells that express low and high levels of HER2 receptors, two 111In-RIC consisting of the anti-HER2 antibody trastuzumab conjugated to NLS or TAT peptides for nuclear delivery. We found that NLS and TAT peptides improved the nuclear uptake of 111In-trastuzumab conjugates, but this effect was limited and non-specific. Moreover, it did not result in a drastic decrease of clonogenic survival. Indium-111 also contributed to non-specific cytotoxicity in vitro due to conversion electrons (30% of the cell killing). Comparison with [125I]I-UdR showed that the energy released in the cell nucleus by increasing the RIC’s nuclear uptake or by choosing an AEE that releases more energy per decay should be 5 to 10 times higher to observe a significant therapeutic effect. Therefore, new Auger-based radiopharmaceuticals need to be developed.
Collapse
Affiliation(s)
- Malick Bio Idrissou
- Institut de Recherche en Cancérologie de Montpellier, Inserm U1194, Université de Montpellier, Institut Régional du Cancer de Montpellier, 34298 Montpellier, France; (M.B.I.); (A.P.); (S.P.)
| | - Alexandre Pichard
- Institut de Recherche en Cancérologie de Montpellier, Inserm U1194, Université de Montpellier, Institut Régional du Cancer de Montpellier, 34298 Montpellier, France; (M.B.I.); (A.P.); (S.P.)
| | - Bryan Tee
- Department of Nuclear Physics, Research School of Physics, Australian National University, Canberra, ACT 2601, Australia; (B.T.); (T.K.)
| | - Tibor Kibedi
- Department of Nuclear Physics, Research School of Physics, Australian National University, Canberra, ACT 2601, Australia; (B.T.); (T.K.)
| | - Sophie Poty
- Institut de Recherche en Cancérologie de Montpellier, Inserm U1194, Université de Montpellier, Institut Régional du Cancer de Montpellier, 34298 Montpellier, France; (M.B.I.); (A.P.); (S.P.)
| | - Jean-Pierre Pouget
- Institut de Recherche en Cancérologie de Montpellier, Inserm U1194, Université de Montpellier, Institut Régional du Cancer de Montpellier, 34298 Montpellier, France; (M.B.I.); (A.P.); (S.P.)
- Correspondence:
| |
Collapse
|
5
|
Pichard A, Marcatili S, Karam J, Constanzo J, Ladjohounlou R, Courteau A, Jarlier M, Bonnefoy N, Patzke S, Stenberg V, Coopman P, Cartron G, Navarro-Teulon I, Repetto-Llamazares A, Heyerdahl H, Dahle J, Bardiès M, Pouget JP. The therapeutic effectiveness of 177Lu-lilotomab in B-cell non-Hodgkin lymphoma involves modulation of G2/M cell cycle arrest. Leukemia 2019; 34:1315-1328. [PMID: 31836849 PMCID: PMC7192854 DOI: 10.1038/s41375-019-0677-4] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/09/2019] [Revised: 11/06/2019] [Accepted: 11/29/2019] [Indexed: 01/02/2023]
Abstract
Some patients with B-cell non-Hodkin lymphoma Lymphoma (NHL) become refractory to rituximab (anti-CD20 antibody) therapy associated with chemotherapy. Here, the effect of the anti-CD37 antibody-radionuclide conjugate lutetium-177 (177Lu)-lilotomab (Betalutin®) was investigated in preclinical models of NHL. In SCID mice bearing DOHH2 (transformed follicular lymphoma, FL) cell xenografts, 177Lu-lilotomab significantly delayed tumor growth, even at low activity (100 MBq/kg). In athymic mice bearing OCI-Ly8 (diffuse large B-cell lymphoma, DLBCL) or Ramos (Burkitt’s lymphoma) cell xenografts, 177Lu-lilotomab activity had to be increased to 500 MBq/kg to show a significant tumor growth delay. Clonogenic and proliferation assays showed that DOHH2 cells were highly sensitive to 177Lu-lilotomab, while Ramos cells were the least sensitive, and U2932 (DLBCL), OCI-Ly8, and Rec-1 (mantle cell lymphoma) cells displayed intermediate sensitivity. The strong 177Lu-lilotomab cytotoxicity observed in DOHH2 cells correlated with reduced G2/M cell cycle arrest, lower WEE-1- and MYT-1-mediated phosphorylation of cyclin-dependent kinase-1 (CDK1), and higher apoptosis. In agreement, 177Lu-lilotomab efficacy in vitro, in vivo, and in patient samples was increased when combined with G2/M cell cycle arrest inhibitors (MK-1775 and PD-166285). These results indicate that 177Lu-lilotomab is particularly efficient in treating tumors with reduced inhibitory CDK1 phosphorylation, such as transformed FL.
Collapse
Affiliation(s)
- Alexandre Pichard
- Institut de Recherche en Cancérologie de Montpellier (IRCM), Inserm U1194, Université de Montpellier, Institut Régional du Cancer de Montpellier (ICM), Montpellier, F-34298, France
| | - Sara Marcatili
- UMR 1037 INSERM/UPS, Centre de Recherche en Cancérologie de Toulouse, Toulouse, F-31062, France
| | - Jihad Karam
- Institut de Recherche en Cancérologie de Montpellier (IRCM), Inserm U1194, Université de Montpellier, Institut Régional du Cancer de Montpellier (ICM), Montpellier, F-34298, France
| | - Julie Constanzo
- Institut de Recherche en Cancérologie de Montpellier (IRCM), Inserm U1194, Université de Montpellier, Institut Régional du Cancer de Montpellier (ICM), Montpellier, F-34298, France
| | - Riad Ladjohounlou
- Institut de Recherche en Cancérologie de Montpellier (IRCM), Inserm U1194, Université de Montpellier, Institut Régional du Cancer de Montpellier (ICM), Montpellier, F-34298, France
| | - Alan Courteau
- UMR 1037 INSERM/UPS, Centre de Recherche en Cancérologie de Toulouse, Toulouse, F-31062, France
| | - Marta Jarlier
- Institut Régional du Cancer de Montpellier (ICM), Montpellier F-34298, France, Montpellier, France
| | - Nathalie Bonnefoy
- Institut de Recherche en Cancérologie de Montpellier (IRCM), Inserm U1194, Université de Montpellier, Institut Régional du Cancer de Montpellier (ICM), Montpellier, F-34298, France
| | - Sebastian Patzke
- Nordic Nanovector ASA, Kjelsåsveien 168 B, 0884, Oslo, Norway.,Department of Radiation Biology, Institute for Cancer Research, OUH-Norwegian Radium Hospital, Oslo, Norway
| | - Vilde Stenberg
- Nordic Nanovector ASA, Kjelsåsveien 168 B, 0884, Oslo, Norway
| | - Peter Coopman
- Institut de Recherche en Cancérologie de Montpellier (IRCM), Inserm U1194, Université de Montpellier, Institut Régional du Cancer de Montpellier (ICM), Montpellier, F-34298, France
| | - Guillaume Cartron
- Département d'Hématologie, UMR-CNRS 5235, CHU de Montpellier, Montpellier, France
| | - Isabelle Navarro-Teulon
- Institut de Recherche en Cancérologie de Montpellier (IRCM), Inserm U1194, Université de Montpellier, Institut Régional du Cancer de Montpellier (ICM), Montpellier, F-34298, France
| | | | - Helen Heyerdahl
- Nordic Nanovector ASA, Kjelsåsveien 168 B, 0884, Oslo, Norway
| | - Jostein Dahle
- Nordic Nanovector ASA, Kjelsåsveien 168 B, 0884, Oslo, Norway
| | - Manuel Bardiès
- UMR 1037 INSERM/UPS, Centre de Recherche en Cancérologie de Toulouse, Toulouse, F-31062, France
| | - Jean-Pierre Pouget
- Institut de Recherche en Cancérologie de Montpellier (IRCM), Inserm U1194, Université de Montpellier, Institut Régional du Cancer de Montpellier (ICM), Montpellier, F-34298, France.
| |
Collapse
|
6
|
Ladjohounlou R, Lozza C, Pichard A, Constanzo J, Karam J, Le Fur P, Deshayes E, Boudousq V, Paillas S, Busson M, Le Blay M, Jarlier M, Marcatili S, Bardiès M, Bruchertseifer F, Morgenstern A, Torgue J, Navarro-Teulon I, Pouget JP. Drugs That Modify Cholesterol Metabolism Alter the p38/JNK-Mediated Targeted and Nontargeted Response to Alpha and Auger Radioimmunotherapy. Clin Cancer Res 2019; 25:4775-4790. [PMID: 31061069 DOI: 10.1158/1078-0432.ccr-18-3295] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/08/2018] [Revised: 03/18/2019] [Accepted: 05/01/2019] [Indexed: 11/16/2022]
Abstract
PURPOSE For the development of new anticancer therapeutic radiopharmaceuticals, including alpha particle emitters, it is important to determine the contribution of targeted effects in irradiated cells, and also of nontargeted effects in nonirradiated neighboring cells, because they may affect the therapeutic efficacy and contribute to side effects. EXPERIMENTAL DESIGN Here, we investigated the contribution of nontargeted cytotoxic and genotoxic effects in vitro and in vivo (in xenografted mice) during alpha (212Pb/212Bi, 213Bi) and Auger (125I) radioimmunotherapy (RIT). RESULTS Between 67% and 94% (alpha RIT) and 8% and 15% (Auger RIT) of cancer cells were killed by targeted effects, whereas 7% to 36% (alpha RIT) and 27% to 29% (Auger RIT) of cells were killed by nontargeted effects. We then demonstrated that the nontargeted cell response to alpha and Auger RIT was partly driven by lipid raft-mediated activation of p38 kinase and JNK. Reactive oxygen species also played a significant role in these nontargeted effects, as demonstrated by NF-κB activation and the inhibitory effects of antioxidant enzymes and radical scavengers. Compared with RIT alone, the use of RIT with ASMase inhibitor (imipramine) or with a lipid raft disruptor (e.g., methyl-beta-cyclodextrin or filipin) led to an increase in clonogenic cell survival in vitro and to larger tumors and less tissue DNA damage in vivo. These results were supported by an inhibitory effect of pravastatin on Auger RIT. CONCLUSIONS Cell membrane-mediated nontargeted effects play a significant role during Auger and alpha RIT, and drugs that modulate cholesterol level, such as statins, could interfere with RIT efficacy.
Collapse
Affiliation(s)
- Riad Ladjohounlou
- IRCM, Institut de Recherche en Cancérologie de Montpellier, INSERM U1194, Université de Montpellier, Institut Régional du Cancer de Montpellier, Montpellier, France
| | - Catherine Lozza
- IRCM, Institut de Recherche en Cancérologie de Montpellier, INSERM U1194, Université de Montpellier, Institut Régional du Cancer de Montpellier, Montpellier, France
| | - Alexandre Pichard
- IRCM, Institut de Recherche en Cancérologie de Montpellier, INSERM U1194, Université de Montpellier, Institut Régional du Cancer de Montpellier, Montpellier, France
| | - Julie Constanzo
- IRCM, Institut de Recherche en Cancérologie de Montpellier, INSERM U1194, Université de Montpellier, Institut Régional du Cancer de Montpellier, Montpellier, France
| | - Jihad Karam
- IRCM, Institut de Recherche en Cancérologie de Montpellier, INSERM U1194, Université de Montpellier, Institut Régional du Cancer de Montpellier, Montpellier, France
| | - Pierre Le Fur
- IRCM, Institut de Recherche en Cancérologie de Montpellier, INSERM U1194, Université de Montpellier, Institut Régional du Cancer de Montpellier, Montpellier, France
| | - Emmanuel Deshayes
- IRCM, Institut de Recherche en Cancérologie de Montpellier, INSERM U1194, Université de Montpellier, Institut Régional du Cancer de Montpellier, Montpellier, France
| | - Vincent Boudousq
- IRCM, Institut de Recherche en Cancérologie de Montpellier, INSERM U1194, Université de Montpellier, Institut Régional du Cancer de Montpellier, Montpellier, France
| | - Salomé Paillas
- IRCM, Institut de Recherche en Cancérologie de Montpellier, INSERM U1194, Université de Montpellier, Institut Régional du Cancer de Montpellier, Montpellier, France
| | - Muriel Busson
- IRCM, Institut de Recherche en Cancérologie de Montpellier, INSERM U1194, Université de Montpellier, Institut Régional du Cancer de Montpellier, Montpellier, France
| | - Marion Le Blay
- IRCM, Institut de Recherche en Cancérologie de Montpellier, INSERM U1194, Université de Montpellier, Institut Régional du Cancer de Montpellier, Montpellier, France
| | - Marta Jarlier
- Institut Régional du Cancer de Montpellier, Université de Montpellier, Montpellier, France
| | - Sara Marcatili
- UMR 1037 INSERM/UPS, Centre de Recherche en Cancérologie de Toulouse, Toulouse, France
| | - Manuel Bardiès
- UMR 1037 INSERM/UPS, Centre de Recherche en Cancérologie de Toulouse, Toulouse, France
| | - Frank Bruchertseifer
- Directorate for Nuclear Safety and Security, European Commission - Joint Research Centre, Karlsruhe, Germany
| | - Alfred Morgenstern
- Directorate for Nuclear Safety and Security, European Commission - Joint Research Centre, Karlsruhe, Germany
| | | | - Isabelle Navarro-Teulon
- IRCM, Institut de Recherche en Cancérologie de Montpellier, INSERM U1194, Université de Montpellier, Institut Régional du Cancer de Montpellier, Montpellier, France
| | - Jean-Pierre Pouget
- IRCM, Institut de Recherche en Cancérologie de Montpellier, INSERM U1194, Université de Montpellier, Institut Régional du Cancer de Montpellier, Montpellier, France.
| |
Collapse
|
7
|
Ashraf Y, Mansouri H, Laurent-Matha V, Alcaraz LB, Roger P, Guiu S, Derocq D, Robin G, Michaud HA, Delpech H, Jarlier M, Pugnière M, Robert B, Puel A, Martin L, Landomiel F, Bourquard T, Achour O, Fruitier-Arnaudin I, Pichard A, Deshayes E, Turtoi A, Poupon A, Simony-Lafontaine J, Boissière-Michot F, Pirot N, Bernex F, Jacot W, du Manoir S, Theillet C, Pouget JP, Navarro-Teulon I, Bonnefoy N, Pèlegrin A, Chardès T, Martineau P, Liaudet-Coopman E. Immunotherapy of triple-negative breast cancer with cathepsin D-targeting antibodies. J Immunother Cancer 2019; 7:29. [PMID: 30717773 PMCID: PMC6360707 DOI: 10.1186/s40425-019-0498-z] [Citation(s) in RCA: 54] [Impact Index Per Article: 10.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/27/2018] [Accepted: 01/01/2019] [Indexed: 01/19/2023] Open
Abstract
BACKGROUND Triple-negative breast cancer (TNBC) treatment is currently restricted to chemotherapy. Hence, tumor-specific molecular targets and/or alternative therapeutic strategies for TNBC are urgently needed. Immunotherapy is emerging as an exciting treatment option for TNBC patients. The aspartic protease cathepsin D (cath-D), a marker of poor prognosis in breast cancer (BC), is overproduced and hypersecreted by human BC cells. This study explores whether cath-D is a tumor cell-associated extracellular biomarker and a potent target for antibody-based therapy in TNBC. METHODS Cath-D prognostic value and localization was evaluated by transcriptomics, proteomics and immunohistochemistry in TNBC. First-in-class anti-cath-D human scFv fragments binding to both human and mouse cath-D were generated using phage display and cloned in the human IgG1 λ format (F1 and E2). Anti-cath-D antibody biodistribution, antitumor efficacy and in vivo underlying mechanisms were investigated in TNBC MDA-MB-231 tumor xenografts in nude mice. Antitumor effect was further assessed in TNBC patient-derived xenografts (PDXs). RESULTS High CTSD mRNA levels correlated with shorter recurrence-free survival in TNBC, and extracellular cath-D was detected in the tumor microenvironment, but not in matched normal breast stroma. Anti-cath-D F1 and E2 antibodies accumulated in TNBC MDA-MB-231 tumor xenografts, inhibited tumor growth and improved mice survival without apparent toxicity. The Fc function of F1, the best antibody candidate, was essential for maximal tumor inhibition in the MDA-MB-231 model. Mechanistically, F1 antitumor response was triggered through natural killer cell activation via IL-15 upregulation, associated with granzyme B and perforin production, and the release of antitumor IFNγ cytokine. The F1 antibody also prevented the tumor recruitment of immunosuppressive tumor-associated macrophages M2 and myeloid-derived suppressor cells, a specific effect associated with a less immunosuppressive tumor microenvironment highlighted by TGFβ decrease. Finally, the antibody F1 inhibited tumor growth of two TNBC PDXs, isolated from patients resistant or not to neo-adjuvant chemotherapy. CONCLUSION Cath-D is a tumor-specific extracellular target in TNBC suitable for antibody-based therapy. Immunomodulatory antibody-based strategy against cath-D is a promising immunotherapy to treat patients with TNBC.
Collapse
Affiliation(s)
- Yahya Ashraf
- IRCM, INSERM, U1194 Univ Montpellier, ICM, 208, rue des Apothicaires, F-34298, Montpellier, Cedex 5, France
| | - Hanane Mansouri
- IRCM, INSERM, U1194 Univ Montpellier, ICM, 208, rue des Apothicaires, F-34298, Montpellier, Cedex 5, France
| | - Valérie Laurent-Matha
- IRCM, INSERM, U1194 Univ Montpellier, ICM, 208, rue des Apothicaires, F-34298, Montpellier, Cedex 5, France
| | - Lindsay B Alcaraz
- IRCM, INSERM, U1194 Univ Montpellier, ICM, 208, rue des Apothicaires, F-34298, Montpellier, Cedex 5, France
| | - Pascal Roger
- IRCM, INSERM, U1194 Univ Montpellier, ICM, 208, rue des Apothicaires, F-34298, Montpellier, Cedex 5, France
- Department of Pathology, CHU Nîmes, Nîmes, France
| | - Séverine Guiu
- IRCM, INSERM, U1194 Univ Montpellier, ICM, 208, rue des Apothicaires, F-34298, Montpellier, Cedex 5, France
- Department of Medical Oncology, ICM, Montpellier, France
| | - Danielle Derocq
- IRCM, INSERM, U1194 Univ Montpellier, ICM, 208, rue des Apothicaires, F-34298, Montpellier, Cedex 5, France
| | - Gautier Robin
- IRCM, INSERM, U1194 Univ Montpellier, ICM, 208, rue des Apothicaires, F-34298, Montpellier, Cedex 5, France
| | - Henri-Alexandre Michaud
- IRCM, INSERM, U1194 Univ Montpellier, ICM, 208, rue des Apothicaires, F-34298, Montpellier, Cedex 5, France
| | - Helène Delpech
- IRCM, INSERM, U1194 Univ Montpellier, ICM, 208, rue des Apothicaires, F-34298, Montpellier, Cedex 5, France
| | | | - Martine Pugnière
- IRCM, INSERM, U1194 Univ Montpellier, ICM, 208, rue des Apothicaires, F-34298, Montpellier, Cedex 5, France
| | - Bruno Robert
- IRCM, INSERM, U1194 Univ Montpellier, ICM, 208, rue des Apothicaires, F-34298, Montpellier, Cedex 5, France
| | - Anthony Puel
- IRCM, INSERM, U1194 Univ Montpellier, ICM, 208, rue des Apothicaires, F-34298, Montpellier, Cedex 5, France
| | - Lucie Martin
- IRCM, INSERM, U1194 Univ Montpellier, ICM, 208, rue des Apothicaires, F-34298, Montpellier, Cedex 5, France
| | | | | | | | | | - Alexandre Pichard
- IRCM, INSERM, U1194 Univ Montpellier, ICM, 208, rue des Apothicaires, F-34298, Montpellier, Cedex 5, France
| | - Emmanuel Deshayes
- IRCM, INSERM, U1194 Univ Montpellier, ICM, 208, rue des Apothicaires, F-34298, Montpellier, Cedex 5, France
| | - Andrei Turtoi
- IRCM, INSERM, U1194 Univ Montpellier, ICM, 208, rue des Apothicaires, F-34298, Montpellier, Cedex 5, France
| | | | | | | | - Nelly Pirot
- Réseau d'Histologie Expérimentale de Montpellier, BioCampus, UMS3426 CNRS-US009 INSERM-UM, Montpellier, France
| | - Florence Bernex
- Réseau d'Histologie Expérimentale de Montpellier, BioCampus, UMS3426 CNRS-US009 INSERM-UM, Montpellier, France
| | - William Jacot
- IRCM, INSERM, U1194 Univ Montpellier, ICM, 208, rue des Apothicaires, F-34298, Montpellier, Cedex 5, France
- Department of Medical Oncology, ICM, Montpellier, France
- Translational Research Unit, ICM, Montpellier, France
| | - Stanislas du Manoir
- IRCM, INSERM, U1194 Univ Montpellier, ICM, 208, rue des Apothicaires, F-34298, Montpellier, Cedex 5, France
| | - Charles Theillet
- IRCM, INSERM, U1194 Univ Montpellier, ICM, 208, rue des Apothicaires, F-34298, Montpellier, Cedex 5, France
| | - Jean-Pierre Pouget
- IRCM, INSERM, U1194 Univ Montpellier, ICM, 208, rue des Apothicaires, F-34298, Montpellier, Cedex 5, France
| | - Isabelle Navarro-Teulon
- IRCM, INSERM, U1194 Univ Montpellier, ICM, 208, rue des Apothicaires, F-34298, Montpellier, Cedex 5, France
| | - Nathalie Bonnefoy
- IRCM, INSERM, U1194 Univ Montpellier, ICM, 208, rue des Apothicaires, F-34298, Montpellier, Cedex 5, France
| | - André Pèlegrin
- IRCM, INSERM, U1194 Univ Montpellier, ICM, 208, rue des Apothicaires, F-34298, Montpellier, Cedex 5, France
| | - Thierry Chardès
- IRCM, INSERM, U1194 Univ Montpellier, ICM, 208, rue des Apothicaires, F-34298, Montpellier, Cedex 5, France
| | - Pierre Martineau
- IRCM, INSERM, U1194 Univ Montpellier, ICM, 208, rue des Apothicaires, F-34298, Montpellier, Cedex 5, France
| | - Emmanuelle Liaudet-Coopman
- IRCM, INSERM, U1194 Univ Montpellier, ICM, 208, rue des Apothicaires, F-34298, Montpellier, Cedex 5, France.
| |
Collapse
|
8
|
Deshayes E, Ladjohounlou R, Le Fur P, Pichard A, Lozza C, Boudousq V, Sevestre S, Jarlier M, Kashani R, Koch J, Sosabowski J, Foster J, Chouin N, Bruchertseifer F, Morgenstern A, Kotzki PO, Navarro-Teulon I, Pouget JP. Radiolabeled Antibodies Against Müllerian-Inhibiting Substance Receptor, Type II: New Tools for a Theranostic Approach in Ovarian Cancer. J Nucl Med 2018; 59:1234-1242. [DOI: 10.2967/jnumed.118.208611] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/20/2018] [Accepted: 02/27/2018] [Indexed: 12/16/2022] Open
|
9
|
Estupina P, Fontayne A, Barret JM, Kersual N, Dubreuil O, Le Blay M, Pichard A, Jarlier M, Pugnière M, Chauvin M, Chardès T, Pouget JP, Deshayes E, Rossignol A, Abache T, de Romeuf C, Terrier A, Verhaeghe L, Gaucher C, Prost JF, Pèlegrin A, Navarro-Teulon I. The anti-tumor efficacy of 3C23K, a glyco-engineered humanized anti-MISRII antibody, in an ovarian cancer model is mainly mediated by engagement of immune effector cells. Oncotarget 2018; 8:37061-37079. [PMID: 28427157 PMCID: PMC5513714 DOI: 10.18632/oncotarget.15715] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/15/2016] [Accepted: 02/11/2017] [Indexed: 01/06/2023] Open
Abstract
Ovarian cancer is the leading cause of death in women with gynecological cancers and despite recent advances, new and more efficient therapies are crucially needed. Müllerian Inhibiting Substance type II Receptor (MISRII, also named AMHRII) is expressed in most ovarian cancer subtypes and is a novel potential target for ovarian cancer immunotherapy. We previously developed and tested 12G4, the first murine monoclonal antibody (MAb) against human MISRII. Here, we report the humanization, affinity maturation and glyco-engineering steps of 12G4 to generate the Fc-optimized 3C23K MAb, and the evaluation of its in vivo anti-tumor activity. The epitopes of 3C23K and 12G4 were strictly identical and 3C23K affinity for MISRII was enhanced by a factor of about 14 (KD = 5.5 × 10−11 M vs 7.9 × 10−10 M), while the use of the EMABling® platform allowed the production of a low-fucosylated 3C23K antibody with a 30-fold KD improvement of its affinity to FcγRIIIa. In COV434-MISRII tumor-bearing mice, 3C23K reduced tumor growth more efficiently than 12G4 and its combination with carboplatin was more efficient than each monotherapy with a mean tumor size of 500, 1100 and 100 mm3 at the end of treatment with 3C23K (10 mg/kg, Q3-4D12), carboplatin (60 mg/kg, Q7D4) and 3C23K+carboplatin, respectively. Conversely, 3C23K-FcKO, a 3C23K form without affinity for the FcγRIIIa receptor, did not display any anti-tumor effect in vivo. These results strongly suggested that 3C23K mechanisms of action are mainly Fc-related. In vitro, antibody-dependent cytotoxicity (ADCC) and antibody-dependent cell phagocytosis (ADCP) were induced by 3C23K, as demonstrated with human effector cells. Using human NK cells, 50% of the maximal lysis was obtained with a 46-fold lower concentration of low-fucosylated 3C23K (2.9 ng/ml) than of 3C23K expressed in CHO cells (133.35 ng/ml). As 3C23K induced strong ADCC with human PBMC but almost none with murine PBMC, antibody-dependent cell phagocytosis (ADCP) was then investigated. 3C23K-dependent (100 ng/ml) ADCP was more active with murine than human macrophages (only 10% of living target cells vs. about 25%). These in vitro results suggest that the reduced ADCC with murine effectors could be partially balanced by ADCP activity in in vivo experiments. Taken together, these preclinical data indicate that 3C23K is a new promising therapeutic candidate for ovarian cancer immunotherapy and justify its recent introduction in a phase I clinical trial.
Collapse
Affiliation(s)
- Pauline Estupina
- IRCM, Institut de Recherche en Cancérologie de Montpellier, Montpellier, F-34298, France.,INSERM, U896, Montpellier, F-34298, France.,Université Montpellier, Montpellier, F-34298, France.,Institut Régional du Cancer de Montpellier, ICM, Montpellier, F-34298, France
| | | | | | - Nathalie Kersual
- IRCM, Institut de Recherche en Cancérologie de Montpellier, Montpellier, F-34298, France.,INSERM, U896, Montpellier, F-34298, France.,Université Montpellier, Montpellier, F-34298, France.,Institut Régional du Cancer de Montpellier, ICM, Montpellier, F-34298, France
| | | | - Marion Le Blay
- IRCM, Institut de Recherche en Cancérologie de Montpellier, Montpellier, F-34298, France.,INSERM, U896, Montpellier, F-34298, France.,Université Montpellier, Montpellier, F-34298, France.,Institut Régional du Cancer de Montpellier, ICM, Montpellier, F-34298, France
| | - Alexandre Pichard
- IRCM, Institut de Recherche en Cancérologie de Montpellier, Montpellier, F-34298, France.,INSERM, U896, Montpellier, F-34298, France.,Université Montpellier, Montpellier, F-34298, France.,Institut Régional du Cancer de Montpellier, ICM, Montpellier, F-34298, France
| | - Marta Jarlier
- Institut Régional du Cancer de Montpellier, ICM, Montpellier, F-34298, France
| | - Martine Pugnière
- IRCM, Institut de Recherche en Cancérologie de Montpellier, Montpellier, F-34298, France.,INSERM, U896, Montpellier, F-34298, France.,Université Montpellier, Montpellier, F-34298, France.,Institut Régional du Cancer de Montpellier, ICM, Montpellier, F-34298, France
| | - Maëva Chauvin
- IRCM, Institut de Recherche en Cancérologie de Montpellier, Montpellier, F-34298, France.,INSERM, U896, Montpellier, F-34298, France.,Université Montpellier, Montpellier, F-34298, France.,Institut Régional du Cancer de Montpellier, ICM, Montpellier, F-34298, France
| | - Thierry Chardès
- IRCM, Institut de Recherche en Cancérologie de Montpellier, Montpellier, F-34298, France.,INSERM, U896, Montpellier, F-34298, France.,Université Montpellier, Montpellier, F-34298, France.,Institut Régional du Cancer de Montpellier, ICM, Montpellier, F-34298, France
| | - Jean-Pierre Pouget
- IRCM, Institut de Recherche en Cancérologie de Montpellier, Montpellier, F-34298, France.,INSERM, U896, Montpellier, F-34298, France.,Université Montpellier, Montpellier, F-34298, France.,Institut Régional du Cancer de Montpellier, ICM, Montpellier, F-34298, France
| | - Emmanuel Deshayes
- Institut Régional du Cancer de Montpellier, ICM, Montpellier, F-34298, France
| | | | | | | | | | | | | | | | - André Pèlegrin
- IRCM, Institut de Recherche en Cancérologie de Montpellier, Montpellier, F-34298, France.,INSERM, U896, Montpellier, F-34298, France.,Université Montpellier, Montpellier, F-34298, France.,Institut Régional du Cancer de Montpellier, ICM, Montpellier, F-34298, France
| | - Isabelle Navarro-Teulon
- IRCM, Institut de Recherche en Cancérologie de Montpellier, Montpellier, F-34298, France.,INSERM, U896, Montpellier, F-34298, France.,Université Montpellier, Montpellier, F-34298, France.,Institut Régional du Cancer de Montpellier, ICM, Montpellier, F-34298, France
| |
Collapse
|
10
|
Maisonial-Besset A, Witkowski T, Navarro-Teulon I, Berthier-Vergnes O, Fois G, Zhu Y, Besse S, Bawa O, Briat A, Quintana M, Pichard A, Bonnet M, Rubinstein E, Pouget JP, Opolon P, Maigne L, Miot-Noirault E, Chezal JM, Boucheix C, Degoul F. Tetraspanin 8 (TSPAN 8) as a potential target for radio-immunotherapy of colorectal cancer. Oncotarget 2017; 8:22034-22047. [PMID: 28423546 PMCID: PMC5400644 DOI: 10.18632/oncotarget.15787] [Citation(s) in RCA: 25] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/12/2016] [Accepted: 01/24/2017] [Indexed: 12/21/2022] Open
Abstract
Tetraspanin 8 (TSPAN8) overexpression is correlated with poor prognosis in human colorectal cancer (CRC). A murine mAb Ts29.2 specific for human TSPAN8 provided significant efficiency for immunotherapy in CRC pre-clinical models. We therefore evaluate the feasability of targeting TSPAN8 in CRC with radiolabeled Ts29.2. Staining of tissue micro-arrays with Ts29.2 revealed that TSPAN8 espression was restricted to a few human healthy tissues. DOTA-Ts29.2 was radiolabeled with 111In or 177Lu with radiochemical purities >95%, specific activity ranging from 300 to 600 MBq/mg, and radioimmunoreactive fractions >80%. The biodistribution of [111In]DOTA-Ts29.2 in nude mice bearing HT29 or SW480 CRC xenografts showed a high specificity of tumor localization with high tumor/blood ratios (HT29: 4.3; SW480-TSPAN8: 3.9 at 72h and 120h post injection respectively). Tumor-specific absorbed dose calculations for [177Lu]DOTA-Ts29.2 was 1.89 Gy/MBq, establishing the feasibility of using radioimmunotherapy of CRC with this radiolabeled antibody. A significant inhibition of tumor growth in HT29 tumor-bearing mice treated with [177Lu]DOTA-Ts29.2 was observed compared to control groups. Ex vivo experiments revealed specific DNA double strand breaks associated with cell apoptosis in [177Lu]DOTA-Ts29.2 treated tumors compared to controls. Overall, we provide a proof-of-concept for the use of [111In/177Lu]DOTA-Ts29.2 that specifically target in vivo aggressive TSPAN8-positive cells in CRC.
Collapse
Affiliation(s)
- Aurelie Maisonial-Besset
- INSERM, U 1240, 63005 Clermont-Ferrand, France.,Université Clermont Auvergne, Imagerie Moléculaire et Thérapie Vectorisée, Clermont-Ferrand, France
| | - Tiffany Witkowski
- INSERM, U 1240, 63005 Clermont-Ferrand, France.,Université Clermont Auvergne, Imagerie Moléculaire et Thérapie Vectorisée, Clermont-Ferrand, France
| | - Isabelle Navarro-Teulon
- IRCM, Institut de Recherche en Cancérologie de Montpellier, Montpellier, France.,INSERM, U896, Montpellier, France.,Université Montpellier 1, Montpellier, France
| | - Odile Berthier-Vergnes
- Université de Lyon 1, Lyon, France.,CNRS, UMR5534, Centre de Génétique et de Physiologie Moléculaires et Cellulaires, Villeurbanne, France
| | - Giovanna Fois
- Université Clermont Auvergne, Imagerie Moléculaire et Thérapie Vectorisée, Clermont-Ferrand, France.,CNRS/IN2P3, UMR6533, Laboratoire de Physique Corpusculaire (LPC), Clermont-Ferrand, France
| | - Yingying Zhu
- INSERM, UMR-S 935, 94800 Villejuif, France.,Université Paris-Sud 11, France.,Université Paris Saclay, France
| | - Sophie Besse
- INSERM, U 1240, 63005 Clermont-Ferrand, France.,Université Clermont Auvergne, Imagerie Moléculaire et Thérapie Vectorisée, Clermont-Ferrand, France
| | - Olivia Bawa
- Gustave Roussy, Laboratoire de Pathologie Expérimentale, 94800 Villejuif, France
| | - Arnaud Briat
- INSERM, U 1240, 63005 Clermont-Ferrand, France.,Université Clermont Auvergne, Imagerie Moléculaire et Thérapie Vectorisée, Clermont-Ferrand, France
| | - Mercedes Quintana
- INSERM, U 1240, 63005 Clermont-Ferrand, France.,Université Clermont Auvergne, Imagerie Moléculaire et Thérapie Vectorisée, Clermont-Ferrand, France
| | - Alexandre Pichard
- IRCM, Institut de Recherche en Cancérologie de Montpellier, Montpellier, France.,INSERM, U896, Montpellier, France.,Université Montpellier 1, Montpellier, France
| | - Mathilde Bonnet
- Université Clermont Auvergne, Imagerie Moléculaire et Thérapie Vectorisée, Clermont-Ferrand, France.,INSERM U1071, Faculté de Médecine, 63000 Clermont Ferrand, France
| | - Eric Rubinstein
- INSERM, UMR-S 935, 94800 Villejuif, France.,Université Paris-Sud 11, France.,Université Paris Saclay, France
| | - Jean-Pierre Pouget
- IRCM, Institut de Recherche en Cancérologie de Montpellier, Montpellier, France.,INSERM, U896, Montpellier, France.,Université Montpellier 1, Montpellier, France
| | - Paule Opolon
- Gustave Roussy, Laboratoire de Pathologie Expérimentale, 94800 Villejuif, France
| | - Lydia Maigne
- Université Clermont Auvergne, Imagerie Moléculaire et Thérapie Vectorisée, Clermont-Ferrand, France.,CNRS/IN2P3, UMR6533, Laboratoire de Physique Corpusculaire (LPC), Clermont-Ferrand, France
| | - Elisabeth Miot-Noirault
- INSERM, U 1240, 63005 Clermont-Ferrand, France.,Université Clermont Auvergne, Imagerie Moléculaire et Thérapie Vectorisée, Clermont-Ferrand, France
| | - Jean-Michel Chezal
- INSERM, U 1240, 63005 Clermont-Ferrand, France.,Université Clermont Auvergne, Imagerie Moléculaire et Thérapie Vectorisée, Clermont-Ferrand, France
| | - Claude Boucheix
- INSERM, UMR-S 935, 94800 Villejuif, France.,Université Paris-Sud 11, France.,Université Paris Saclay, France
| | - Françoise Degoul
- INSERM, U 1240, 63005 Clermont-Ferrand, France.,Université Clermont Auvergne, Imagerie Moléculaire et Thérapie Vectorisée, Clermont-Ferrand, France
| |
Collapse
|
11
|
Buchanan K, Alraies M, Rogers T, Steinvil A, Kajita A, Koifman E, Xu L, Torguson R, Lipinski M, Garcia-Garcia H, Ben-Dor I, Pichard A, Satler L, Waksman R, Asch F. P4227Role of contractile reserve as a predictor of mortality in low-flow, low-gradient severe aortic stenosis patients following transcatheter aortic valve replacement. Eur Heart J 2017. [DOI: 10.1093/eurheartj/ehx504.p4227] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
12
|
Marcatili S, Pichard A, Courteau A, Ladjohounlou R, Navarro-Teulon I, Repetto-Llamazares A, Heyerdahl H, Dahle J, Pouget JP, Bardiès M. Realistic multi-cellular dosimetry for177Lu-labelled antibodies: model and application. Phys Med Biol 2016; 61:6935-6952. [DOI: 10.1088/0031-9155/61/19/6935] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
|
13
|
Paillas S, Ladjohounlou R, Lozza C, Pichard A, Boudousq V, Jarlier M, Sevestre S, Le Blay M, Deshayes E, Sosabowski J, Chardès T, Navarro-Teulon I, Mairs RJ, Pouget JP. Localized Irradiation of Cell Membrane by Auger Electrons Is Cytotoxic Through Oxidative Stress-Mediated Nontargeted Effects. Antioxid Redox Signal 2016; 25:467-84. [PMID: 27224059 PMCID: PMC5028911 DOI: 10.1089/ars.2015.6309] [Citation(s) in RCA: 58] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
AIMS We investigated whether radiation-induced nontargeted effects are involved in the cytotoxic effects of anticell surface monoclonal antibodies labeled with Auger electron emitters, such as iodine 125 (monoclonal antibodies labeled with (125)I [(125)I-mAbs]). RESULTS We showed that the cytotoxicity of (125)I-mAbs targeting the cell membrane of p53(+/+) HCT116 colon cancer cells is mainly due to nontargeted effects. Targeted and nontargeted cytotoxicities were inhibited in vitro following lipid raft disruption with Methyl-β-cyclodextrin (MBCD) or filipin or use of radical oxygen species scavengers. (125)I-mAb efficacy was associated with acid sphingomyelinase activation and modulated through activation of the AKT, extracellular signal-related kinase ½ (ERK1/2), p38 kinase, c-Jun N-terminal kinase (JNK) signaling pathways, and also of phospholipase C-γ (PLC-γ), proline-rich tyrosine kinase 2 (PYK-2), and paxillin, involved in Ca(2+) fluxes. Moreover, the nontargeted response induced by directing 5-[(125)I]iodo-2'-deoxyuridine to the nucleus was comparable to that of (125)I-mAb against cell surface receptors. In vivo, we found that the statistical significance of tumor growth delay induced by (125)I-mAb was removed after MBCD treatment and observed oxidative DNA damage beyond the expected Auger electron range. These results suggest the involvement of nontargeted effects in vivo also. INNOVATION Low-energy Auger electrons, such as those emitted by (125)I, have a short tissue range and are usually targeted to the nucleus to maximize their cytotoxicity. In this study, we show that targeting the cancer cell surface with (125)I-mAbs produces a lipid raft-mediated nontargeted response that compensates for the inferior efficacy of non-nuclear targeting. CONCLUSION Our findings describe the mechanisms involved in the efficacy of (125)I-mAbs targeting the cancer cell surface. Antioxid. Redox Signal. 25, 467-484.
Collapse
Affiliation(s)
- Salomé Paillas
- 1 Institut de Recherche en Cancérologie de Montpellier (IRCM) , Montpellier, France .,2 INSERM , U1194, Montpellier, France .,3 Université de Montpellier , Montpellier, France .,4 Institut régional du Cancer de Montpellier , Montpellier, France .,5 Barts Cancer Institute, Queen Mary University of London , London, United Kingdom
| | - Riad Ladjohounlou
- 1 Institut de Recherche en Cancérologie de Montpellier (IRCM) , Montpellier, France .,2 INSERM , U1194, Montpellier, France .,3 Université de Montpellier , Montpellier, France .,4 Institut régional du Cancer de Montpellier , Montpellier, France
| | - Catherine Lozza
- 1 Institut de Recherche en Cancérologie de Montpellier (IRCM) , Montpellier, France .,2 INSERM , U1194, Montpellier, France .,3 Université de Montpellier , Montpellier, France .,4 Institut régional du Cancer de Montpellier , Montpellier, France
| | - Alexandre Pichard
- 1 Institut de Recherche en Cancérologie de Montpellier (IRCM) , Montpellier, France .,2 INSERM , U1194, Montpellier, France .,3 Université de Montpellier , Montpellier, France .,4 Institut régional du Cancer de Montpellier , Montpellier, France
| | - Vincent Boudousq
- 1 Institut de Recherche en Cancérologie de Montpellier (IRCM) , Montpellier, France .,2 INSERM , U1194, Montpellier, France .,3 Université de Montpellier , Montpellier, France .,4 Institut régional du Cancer de Montpellier , Montpellier, France
| | - Marta Jarlier
- 4 Institut régional du Cancer de Montpellier , Montpellier, France
| | - Samuel Sevestre
- 1 Institut de Recherche en Cancérologie de Montpellier (IRCM) , Montpellier, France .,2 INSERM , U1194, Montpellier, France .,3 Université de Montpellier , Montpellier, France .,4 Institut régional du Cancer de Montpellier , Montpellier, France
| | - Marion Le Blay
- 1 Institut de Recherche en Cancérologie de Montpellier (IRCM) , Montpellier, France .,2 INSERM , U1194, Montpellier, France .,3 Université de Montpellier , Montpellier, France .,4 Institut régional du Cancer de Montpellier , Montpellier, France
| | - Emmanuel Deshayes
- 1 Institut de Recherche en Cancérologie de Montpellier (IRCM) , Montpellier, France .,2 INSERM , U1194, Montpellier, France .,3 Université de Montpellier , Montpellier, France .,4 Institut régional du Cancer de Montpellier , Montpellier, France
| | - Jane Sosabowski
- 5 Barts Cancer Institute, Queen Mary University of London , London, United Kingdom
| | - Thierry Chardès
- 1 Institut de Recherche en Cancérologie de Montpellier (IRCM) , Montpellier, France .,2 INSERM , U1194, Montpellier, France .,3 Université de Montpellier , Montpellier, France .,4 Institut régional du Cancer de Montpellier , Montpellier, France
| | - Isabelle Navarro-Teulon
- 1 Institut de Recherche en Cancérologie de Montpellier (IRCM) , Montpellier, France .,2 INSERM , U1194, Montpellier, France .,3 Université de Montpellier , Montpellier, France .,4 Institut régional du Cancer de Montpellier , Montpellier, France
| | - Robert J Mairs
- 6 Institute of Cancer Sciences, University of Glasgow , Glasgow, Scotland
| | - Jean-Pierre Pouget
- 1 Institut de Recherche en Cancérologie de Montpellier (IRCM) , Montpellier, France .,2 INSERM , U1194, Montpellier, France .,3 Université de Montpellier , Montpellier, France .,4 Institut régional du Cancer de Montpellier , Montpellier, France
| |
Collapse
|
14
|
Ladjohounlou R, Pichard A, Boudousq V, Paillas S, Le Blay M, Lozza C, Marcatili S, Bardiès M, Torgue J, Navarro-Teulon I, Pouget JP. Contribution of direct and bystander effects to therapeutic efficacy of alpha-RIT using 212Pb-labeled mAbs. Radiother Oncol 2016. [DOI: 10.1016/s0167-8140(16)30175-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
15
|
Repetto-Llamazares AHV, Larsen RH, Patzke S, Fleten KG, Didierlaurent D, Pichard A, Pouget JP, Dahle J. Targeted Cancer Therapy with a Novel Anti-CD37 Beta-Particle Emitting Radioimmunoconjugate for Treatment of Non-Hodgkin Lymphoma. PLoS One 2015; 10:e0128816. [PMID: 26066655 PMCID: PMC4466226 DOI: 10.1371/journal.pone.0128816] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/09/2015] [Accepted: 04/30/2015] [Indexed: 12/31/2022] Open
Abstract
177Lu-DOTA-HH1 (177Lu-HH1) is a novel anti-CD37 radioimmunoconjugate developed to treat non-Hodgkin lymphoma. Mice with subcutaneous Ramos xenografts were treated with different activities of 177Lu-HH1, 177Lu-DOTA-rituximab (177Lu-rituximab) and non-specific 177Lu-DOTA-IgG1 (177Lu-IgG1) and therapeutic effect and toxicity of the treatment were monitored. Significant tumor growth delay and increased survival of mice were observed in mice treated with 530 MBq/kg 177Lu-HH1 as compared with mice treated with similar activities of 177Lu-rituximab or non-specific 177Lu-IgG1, 0.9% NaCl or unlabeled HH1. All mice injected with 530 MBq/kg of 177Lu-HH1 tolerated the treatment well. In contrast, 6 out of 10 mice treated with 530 MBq/kg 177Lu-rituximab experienced severe radiation toxicity. The retention of 177Lu-rituximab in organs of the mononuclear phagocyte system was longer than for 177Lu-HH1, which explains the higher toxicity observed in mice treated with 177Lu-rituximab. In vitro internalization studies showed that 177Lu-HH1 internalizes faster and to a higher extent than 177Lu-rituximab which might be the reason for the better therapeutic effect of 177Lu-HH1.
Collapse
MESH Headings
- Animals
- Antibodies/chemistry
- Antibodies/immunology
- Antigen-Antibody Reactions
- Antigens, Neoplasm/chemistry
- Antigens, Neoplasm/immunology
- Antigens, Neoplasm/metabolism
- Beta Particles
- Cell Line, Tumor
- Disease Models, Animal
- Humans
- Immunoconjugates/chemistry
- Immunoconjugates/pharmacokinetics
- Immunoconjugates/therapeutic use
- Iodine Radioisotopes/chemistry
- Lutetium/chemistry
- Lymphoma, Non-Hodgkin/drug therapy
- Lymphoma, Non-Hodgkin/mortality
- Lymphoma, Non-Hodgkin/pathology
- Mice
- Mice, Nude
- Radioisotopes
- Radiopharmaceuticals/chemistry
- Radiopharmaceuticals/pharmacokinetics
- Radiopharmaceuticals/therapeutic use
- Rituximab/chemistry
- Rituximab/immunology
- Tetraspanins/chemistry
- Tetraspanins/immunology
- Tetraspanins/metabolism
- Tissue Distribution
- Transplantation, Heterologous
Collapse
Affiliation(s)
- Ada H. V. Repetto-Llamazares
- Nordic Nanovector ASA, Kjelsåsveien 168, 0884, Oslo, Norway
- Department of Radiation Biology, Institute for Cancer Research, Oslo University Hospital, Montebello, 0310, Oslo, Norway
- * E-mail:
| | | | - Sebastian Patzke
- Department of Radiation Biology, Institute for Cancer Research, Oslo University Hospital, Montebello, 0310, Oslo, Norway
| | - Karianne G. Fleten
- Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital, Montebello, 0310, Oslo, Norway
| | - David Didierlaurent
- UMR 1037 INSERM/UPS, Centre de Recherche en Cancérologie de Toulouse, Toulouse, F-31062, France
| | - Alexandre Pichard
- Institut de Recherche en Cancérologie de Montpellier, Institut National de la Santé et de la Recherche Médicale, U896, Université Montpellier, Montpellier, France
| | - Jean Pierre Pouget
- Institut de Recherche en Cancérologie de Montpellier, Institut National de la Santé et de la Recherche Médicale, U896, Université Montpellier, Montpellier, France
| | - Jostein Dahle
- Nordic Nanovector ASA, Kjelsåsveien 168, 0884, Oslo, Norway
| |
Collapse
|
16
|
Pouget JP, Pichard A, Boudousq V, Bobyk L, Ladjohounlou R, Paillas S, Le Blay M, Busson M, Lozza C, Maquaire P, Torgue J, Navarro-Teulon I. 159: ²¹²Pb-labeled mAbs targeting CEA or HER2 during α-RIT of small peritoneal carcinomatosis – Dose effect relationship? Radiother Oncol 2014. [DOI: 10.1016/s0167-8140(15)34180-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
17
|
Waksman R, Kitabata H, Dvir D, Loh J, Torguson R, Chen F, Satler L, Pichard A. Comparison of stent axial integrity in first- versus second-generation drug-eluting stents: insights from intravascular ultrasound analysis. Eur Heart J 2013. [DOI: 10.1093/eurheartj/eht309.p3045] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
18
|
Lehérissier P, Bajeat O, Barué C, Canet C, Dubois M, Dupuis M, Flambard JL, Frigot R, Jardin P, Leboucher C, Lemagnen F, Maunoury L, Osmond B, Pacquet JY, Pichard A, Thuillier T, Peaucelle C. Status of the ion sources developments for the Spiral2 project at GANIL. Rev Sci Instrum 2012; 83:02A915. [PMID: 22380256 DOI: 10.1063/1.3678677] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/31/2023]
Abstract
The SPIRAL 2 facility is now under construction and will deliver either stable or radioactive ion beams. First tests of nickel beam production have been performed at GANIL with a new version of the large capacity oven, and a calcium beam has been produced on the heavy ion low energy beam transport line of SPIRAL 2, installed at LPSC Grenoble. For the production of radioactive beams, several target∕ion-source systems (TISSs) are under development at GANIL as the 2.45 GHz electron cyclotron resonance ion source, the surface ionization source, and the oven prototype for heating the uranium carbide target up to 2000 °C. The existing test bench has been upgraded for these developments and a new one, dedicated for the validation of the TISS before mounting in the production module, is under design. Results and current status of these activities are presented.
Collapse
Affiliation(s)
- P Lehérissier
- GANIL, Grand Accélérateur National d'Ions Lourds, CEA-DSM∕CNRS-IN2P3, Bvd H. Becquerel, BP 55027 14076 Caen Cedex 5, France.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
19
|
Lecesne N, Alvès-Condé R, Coterreau E, De Oliveira F, Dubois M, Flambard JL, Franberg H, Gottwald T, Jardin P, Lassen J, Le Blanc F, Leroy R, Mattolat C, Olivier A, Pacquet JY, Pichard A, Rothe S, Saint-Laurent MG, Wendt K. GISELE: a resonant ionization laser ion source for the production of radioactive ions at GANIL. Rev Sci Instrum 2010; 81:02A910. [PMID: 20192407 DOI: 10.1063/1.3279301] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/28/2023]
Abstract
SPIRAL2 is the new project under construction at GANIL to produce radioactive ion beams and in particular neutron rich ion beams. For the past 10 yr SPIRAL1 at GANIL has been delivering accelerated radioactive ion beams of gases. Both facilities now need to extend the range of radioactive ion beams produced to condensable elements. For that purpose, a resonant ionization laser ion source, funded by the French Research National Agency, is under development at GANIL, in collaboration with IPN Orsay, University of Mainz (Germany) and TRIUMF, Vancouver (Canada). A description of this project called GISELE (GANIL Ion Source using Electron Laser Excitation) is presented.
Collapse
Affiliation(s)
- N Lecesne
- GANIL, BP 55027, 14076 Caen Cedex 5, France.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
20
|
Jardin P, Barué C, Bajeat O, Canet C, Clément E, Cornell JC, Delahaye P, Dubois M, Dupuis M, Flambard JL, Frånberg H, Frigot R, Leboucher C, Lecesne N, Lecomte P, Lehérissier P, Lemagnen F, Leroy R, Maunoury L, Méry A, De Oliveira F, Pichard A, Pacquet JY, Saint-Laurent MG, Thomas JC. Latest developments at GANIL for stable and radioactive ion beam production. Rev Sci Instrum 2010; 81:02A909. [PMID: 20192406 DOI: 10.1063/1.3267296] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/28/2023]
Abstract
In the frame of the SPIRAL II (Système de Production d'Ions Radioactifs Accélérés en Ligne Partie II) project, several developments of stable and radioactive ion production systems have been started up. In parallel, GANIL has the ambition to preserve the existing stable and radioactive beams and also to increase its range by offering new ones. In order to identify the best directions for this development, a new group called GANISOL has been formed. Its preliminary conclusions and the latest developments at GANIL are presented.
Collapse
Affiliation(s)
- P Jardin
- Grand Accélérateur National d'Ions Lourds, Bd H. Becquerel, BP 55027, 14076 Caen Cedex 5, France
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
21
|
Pichard A, Jardin P, Saint-Laurent MG, Frigot R, Bajeat O, Delahaye P, Dubois M, Frånberg-Delahaye H, Lecomte P, Lehérissier P, Leroy R, Lecesne N, Maunoury L, Méry A, Pacquet JY. Development of a surface ionization source for the SPIRAL 2 project. Rev Sci Instrum 2010; 81:02A908. [PMID: 20225406 DOI: 10.1063/1.3258498] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/28/2023]
Abstract
Development of new radioactive beams, and thus of new target ion sources (TISs) for isotope-separator-on-line production systems are in progress at GANIL for the SPIRAL 2 project. The efficiency and time response measurements of each step in the production process are crucial to predict and maximize the available yields, in particular, for short lived isotopes. This paper presents a method for measuring these quantities that makes use of a stable alkali chopped beam of controlled intensity. This method was applied to surface ionization source test for high efficiency. Results of recent experiments are presented that include ionization efficiency measurements for Cs, Rb, K, Na, and Li with a graphite and rhenium ionizer and dwell time of these alkalis on graphite. The results enabled to design a first surface ionization source prototype which will be installed in the SPIRAL 2 TIS.
Collapse
Affiliation(s)
- A Pichard
- GANIL, Bd Henri Becquerel, BP 55027, 14076 Caen Cedex 5, France.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
22
|
Méry A, Jardin P, Alcántara-Núñez J, Saint-Laurent MG, Bajeat O, Delahaye P, Dubois M, Frånberg-Delahaye H, Lecomte P, Lehérissier P, Maunoury L, Pichard A, Pacquet JY, Thomas JC. Direct 1+ --> N+ conversion of stable alkali ions using an electron cyclotron resonance ion source. Rev Sci Instrum 2010; 81:02A904. [PMID: 20192402 DOI: 10.1063/1.3267782] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/28/2023]
Abstract
The production of radioactive ions using the Isotope Separation On-Line method gives rise, in most cases, to singly charged ions. In order to perform experiments with postaccelerated radioactive ion beams, these ions have to be multicharged. We describe here a new compact design for a charge breeder that will be coupled to the production target of SPIRAL1 at GANIL. We present recent results obtained offline with stable alkali ions (Na, K, Rb, and Cs) on the SIRa test bench. Particularly, 1(+) to N(+) conversion efficiencies and conversion times are presented. Several points have been identified for the improvements of the present performances.
Collapse
Affiliation(s)
- A Méry
- GANIL, Bd Henri Becquerel, BP 55027, 14076 CAEN Cedex 5, France.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
23
|
Lecesne N, Eleon C, Feierstein C, Gaubert G, Huguet Y, Jardin P, Lemagnen F, Leroy R, Pacquet JY, Pellemoine F, Pichard A, Bajeat O, Essabaa S, Lau C, Launay F, Serani L, Demonchy CE. The radioactive ion beam production systems for the SPIRAL2 project. Rev Sci Instrum 2008; 79:02A907. [PMID: 18315162 DOI: 10.1063/1.2823895] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/26/2023]
Abstract
The SPIRAL2 project, currently under construction at GANIL, will include an isotope separator on line based facility for the production and acceleration of radioactive ion beams. A superconducting linear accelerator will accelerate 5 mA deuterons up to 40 MeV and 1 mA heavy ions up to 14.5 MeV/u. These primary beams will be used to bombard both thick and thin targets. We are investigating three different techniques to produce the radioactive ion beams: (1) the neutron induced fission of uranium carbide, (2) the direct interaction of deuterons in a uranium carbide target, and (3) the interaction of a heavy ion beam with a target. All these production systems will be coupled to an ion source. Four kinds of ion sources are foreseen for the ionization of the radioactive atoms: an electron cyclotron resonance ion source, a surface ionization ion source, a forced electron beam induced arc discharge ion source, and a laser ion source depending on the characteristics of the desired radioactive ion beam in terms of intensity, efficiency, purity, etc. A presentation of the SPIRAL2 project and of the different production systems is given.
Collapse
Affiliation(s)
- N Lecesne
- GANIL, BP55027-14076, Caen Cedex 5, France.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
24
|
Pichard A. [Antithrombotic agents in clinical practice]. Arch Mal Coeur Vaiss 2006; 99 Spec no.3:23-5. [PMID: 16553240] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/07/2023]
Abstract
The accumulation of evidence of efficacy and tolerance led to the FDA approval of bivalirudine in the United States and it has progressively replaced the use of unfractionated heparin in its traditional indication in the catheter laboratory of the Washington Hospital Center. This change has probably contributed to the reduction of bleeding complications observed in this institution. The experience acquired also showed a reduced risk of enzyme rises after the procedure. The use of bivalirudine in conditions comparable to those of the REPLACE II trial confirms that anti GPIIb/IIIa molecules should be reserved for extreme circumstances rather than be systematically associated with heparin, so significantly reducing the cost of the interventional procedures.
Collapse
Affiliation(s)
- A Pichard
- Cardiac Catheterization Labs, Washington Hospital Center, DC, USA
| |
Collapse
|
25
|
Hadengue P, Gennart J, Legalland J, Nicoulet I, Pichard A, Poot B, Thouzeau A, Gilbert D. Évaluation des risques sanitaires des raffineries. Guide méthodologique. ARCH MAL PROF ENVIRO 2004. [DOI: 10.1016/s1775-8785(04)93060-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
26
|
Lew R, Satler L, Pichard A, Suddath W, Laird J, Kent K, Sharretts J, Waksman R. Management of severely calcified right coronary artery. Cardiovasc Radiat Med 2003; 4:116-7. [PMID: 14650411 DOI: 10.1016/s1522-1865(03)00146-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 04/27/2023]
Affiliation(s)
- R Lew
- Washington Hospital Center, Washington, DC, USA
| | | | | | | | | | | | | | | |
Collapse
|
27
|
Lew R, Satler L, Pichard A, Slack M, Kent K, Laird J, Suddath W, Sharretts J, Waksman R. Persistent right to left shunt post PFO closure for recurrent CVAs. Cardiovasc Radiat Med 2003; 4:51. [PMID: 12966941 DOI: 10.1016/s1522-1865(03)00140-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Affiliation(s)
- R Lew
- Washington Hospital Center, DC 20010, USA
| | | | | | | | | | | | | | | | | |
Collapse
|
28
|
Lew R, Satler L, Laird J, Pichard A, Suddath W, Waksman R. Perfusion of the left arm via a LIMA graft. Cardiovasc Radiat Med 2002; 3:263. [PMID: 12974380 DOI: 10.1016/s1522-1865(03)00109-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Affiliation(s)
- R Lew
- Washington Hospital Center, 110 Irving Street, NW, Washington, DC 20010, USA
| | | | | | | | | | | |
Collapse
|
29
|
Escobar J, Guarda E, Marchant E, Fajuri A, Martínez A, Pichard A. Relation of stenting to decreased coronary blood flow during primary angioplasty in acute myocardial infarction. Am J Cardiol 2001; 88:1410-2, A6. [PMID: 11741561 DOI: 10.1016/s0002-9149(01)02121-x] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- J Escobar
- Department of Cardiovascular Diseases, Catholic University of Chile, Santiago, Chile
| | | | | | | | | | | |
Collapse
|
30
|
Shiran A, Weissman NJ, Leiboff B, Kent KM, Pichard A, Satler LF, Wu H, Leon MB, Mintz GS. Effect of preintervention plaque burden on subsequent intimal hyperplasia in stented coronary artery lesions. Am J Cardiol 2000; 86:1318-21. [PMID: 11113405 DOI: 10.1016/s0002-9149(00)01234-0] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Abstract
We sought to determine if axial and circumferential distribution of plaque before stenting determines the axial and circumferential distribution of subsequent intimal hyperplasia (IH). We studied 22 patients with a single Palmaz-Schatz stent implanted in a native coronary artery, who underwent intravascular ultrasound (IVUS) imaging before intervention, after stenting, and at 6-month follow-up. For each lesion, 7 locations were analyzed: proximal and distal reference, proximal and distal edge of the stent, proximal and distal location within the body of the stent, and the articulation. Pre- and postintervention and follow-up image slices were precisely aligned and analyzed for pre- and postintervention plaque area and follow-up IH area and thickness. The location of maximal IH area was at or adjacent to the location of maximal preintervention plaque in 17 of 22 of the patients (77%). Similiarly, the circumferential distribution of IH at follow-up paralleled the eccentricity pattern of the native plaque burden in 69% (24 of 35 slices). Using multivariant analysis, the strongest predictor of IH was preintervention plaque area (p = 0.001). IH accumulates axially and circumferentially preferentially at the site of maximal preintervention plaque.
Collapse
Affiliation(s)
- A Shiran
- Intravascular Ultrasound Imaging and Cardiac Catheterization Laboratories, Washington Hospital Center, DC 20010, USA
| | | | | | | | | | | | | | | | | |
Collapse
|
31
|
Mastoor M, Bonnet Y, Pinnow E, Ellahham S, Lindsay J, Pichard A. New device angioplasty: gender differences in utilization and outcome. J Am Coll Cardiol 1998. [DOI: 10.1016/s0735-1097(98)80636-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
32
|
Tebeica M, Mastoor M, Plude G, Mehran R, Pinnow E, Slacker S, Bucher T, Popma J, Pichard A, Lindsay J. Stent use in internal mammary graft angioplasty — a 4-year experience. J Am Coll Cardiol 1998. [DOI: 10.1016/s0735-1097(98)81074-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
33
|
Goldstein SA, Campbell A, Mintz GS, Pichard A, Leon M, Lindsay J. Feasibility of on-line transesophageal echocardiography during balloon mitral valvulotomy: experience with 93 patients. J Heart Valve Dis 1994; 3:136-48. [PMID: 8012630] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
Percutaneous balloon mitral valvulotomy (PBMV) has become an established method of treating symptomatic patients with rheumatic mitral stenosis. PBMV is performed with fluoroscopic guidance alone in most centres. However, even experienced operators can be misled by radiographic anatomic landmarks. Transesophageal echocardiography (TEE) provides high-quality images of the atrial septum, left atrium, mitral valve, and surrounding structures and has a number of unique advantages that make it a useful adjunct to fluoroscopy for guidance and monitoring of patients during PBMV. The aim of this study was to demonstrate the feasibility, safety, and utility of on-line TEE during PBMV on awake patients. TEE was performed on 93 consciously sedated, awake patients in the cardiac catheterisation laboratory during PBMV. Ninety five patients were successfully intubated in the supine position. Two patients were excluded from PBMV based on mobile thrombi near the mouth of the left atrial appendage. The TEE was well-tolerated in the 93 patients who underwent PBMV, and no complications of TEE were detected. Major complications of PBMV were detected in 7 patients (severe MR, n = 3; tamponade, n = 1; large ASD, n = 3). We conclude that on-line TEE during PBMV is feasible, safe, and well tolerated. TEE-guidance facilitates transseptal catheterization and proper positioning of balloon catheters across the mitral orifice. TEE can help monitor the adequacy of PBMV and help decide whether or not subsequent dilatations are necessary. TEE can rapidly detect complications and thereby guide appropriate management of these complications.
Collapse
Affiliation(s)
- S A Goldstein
- Division of Cardiology, Washington Hospital Centre, Washington, DC 10010
| | | | | | | | | | | |
Collapse
|
34
|
Litvack F, Eigler N, Margolis J, Rothbaum D, Bresnahan JF, Holmes D, Untereker W, Leon M, Kent K, Pichard A. Percutaneous excimer laser coronary angioplasty: results in the first consecutive 3,000 patients. The ELCA Investigators. J Am Coll Cardiol 1994; 23:323-9. [PMID: 8294681 DOI: 10.1016/0735-1097(94)90414-6] [Citation(s) in RCA: 122] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
OBJECTIVES We report the comprehensive results of the first consecutive 3,000 patients treated in an excimer laser coronary angioplasty registry. BACKGROUND Excimer laser coronary angioplasty involves the use of a pulsed, 308-nm ultraviolet laser transmitted by optical fibers to reduce coronary stenoses. Preliminary reports have described safety and efficacy profiles in small numbers of patients. METHODS Patients were enrolled in a prospective, nonrandomized manner. The catheters used were 1.3, 1.6, 2.0, 2.2 and 2.4 mm in diameter, at energy densities up to 70 mJ/mm2. Procedures were performed by standard angioplasty technique with conventional guide catheters. RESULTS Seventy-five percent of patients were male, 68% were in Canadian Cardiovascular Society functional class III or IV and the cohort included 3,592 lesions. Procedural success (final stenosis < or = 50% without in-hospital Q wave myocardial infarction, coronary artery bypass surgery or death) was 90% and did not differ between the first 2,000 and the last 1,000 patients treated. There was no significant difference in success or complication rates with respect to lesion length, nor were there differences between selected complex and simple lesions. Complications included in-hospital bypass surgery (3.8%), Q wave myocardial infarction (2.1%) and death (0.5%). Coronary artery perforation occurred in 1.2% of patients (1% of lesions) but significantly decreased to 0.4% in the last 1,000 patients (0.3% of lesions). Angiographic dissection occurred in 13% of lesions, transient occlusion in 3.4% and sustained occlusion in 3.1%. Comprehensive lesion morphologic data collected in the latter portion of the study showed the procedure predominantly limited to American College of Cardiology-American Heart Association type B2 and C lesions, with no significant difference in short-term outcome between groups. CONCLUSIONS Excimer laser angioplasty can be safely and effectively applied, even in a variety of complex lesions not well suited for percutaneous transluminal coronary angioplasty. These types may include aorto-ostial, long lesions, total occlusions crossable with a wire, diffuse disease and vein grafts. Most recent data show a trend for the selection of predominantly complex lesions and a reduction in the incidence of perforation. This procedure may broaden the therapeutic window for the interventional treatment of selected complex coronary artery disease.
Collapse
Affiliation(s)
- F Litvack
- Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California
| | | | | | | | | | | | | | | | | | | |
Collapse
|
35
|
Martinez A, Pichard A, Little T, Lindsay J. Probe "balloon on a wire" ultra-low-profile coronary catheter: results of PTCA in 107 patients. Cathet Cardiovasc Diagn 1989; 18:222-6. [PMID: 2605624 DOI: 10.1002/ccd.1810180406] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
A new low-profile "balloon-on-a-wire" angioplasty catheter, the Probe (USCI), was used in 107 patients over a 4-month period. Twenty-nine patients had stable angina, 59 had unstable angina, and 19 had had myocardial infarction (MI) 3 to 15 days prior to the procedure; 71 patients had single-vessel and 36 had multi-vessel disease. In this series, 57 lesions were defined as complex. Successful dilatation was defined as a residual stenosis of less than 30%. Of 132 non-total obstructions, 127 (97%) were successfully dilated. Two distal lesions could not be reached, two lesions could not be crossed by the balloon, and a distal lesion dilatation resulted in acute closure in one case. Of 19 total obstructions, 16 (84%) were successfully dilated (mean residual stenosis 23%). The wire tip was unable to cross the lesion in the three unsuccessful procedures. Seven complications occurred in the series, all involving non-total obstructions: closure of a distal vessel and a side branch caused no clinical symptoms or EKG changes; three local dissections were tacked back with repeat dilatation; and two longitudinal dissections caused no apparent reduction in luminal diameter. The Probe's low-profile and exceptional trackability enabled it to cross very tight lesions with minimal trauma to the vessel wall. The high degree of conformability of the PET balloon minimizes vessel straightening or sheer forces and appears to reduce the potential for dissection. The device may therefore extend the indications and ease of PTCA while reducing complications of the procedure.
Collapse
Affiliation(s)
- A Martinez
- Department of Medicine, Washington Hospital Center, D.C. 20010
| | | | | | | |
Collapse
|
36
|
Kalan JM, Mann JM, Leon MB, Pichard A, Kent KM, Roberts WC. Morphologic findings in stenotic aortic valves that have had "successful" percutaneous balloon valvuloplasty. Am J Cardiol 1988; 62:152-4. [PMID: 3381736 DOI: 10.1016/0002-9149(88)91385-9] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
Affiliation(s)
- J M Kalan
- Pathology Branche, National Heart, Lung, and Blood Institute, Bethesda, Maryland
| | | | | | | | | | | |
Collapse
|
37
|
Affiliation(s)
- N Hamad
- Washington Hospital Center, Washington, DC 20010
| | | | | | | | | |
Collapse
|
38
|
Affiliation(s)
- N Hamad
- Washington Hospital Center, Washington, DC
| | | | | | | |
Collapse
|
39
|
Affiliation(s)
- N Hamad
- Washington Hospital Center, Washington, DC
| | | | | |
Collapse
|
40
|
|
41
|
|
42
|
Lee G, Garcia JM, Corso PJ, Chan MC, Rink JL, Pichard A, Lee KK, Reis RL, Mason DT. Correlation of coronary angioscopic to angiographic findings in coronary artery disease. Am J Cardiol 1986; 58:238-41. [PMID: 3488672 DOI: 10.1016/0002-9149(86)90054-8] [Citation(s) in RCA: 40] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
Abstract
An Olympus ultrathin fiberscope, 1.8 mm outer diameter, was inserted intraluminally into 11 stenoses of the left anterior descending and circumflex coronary arteries in 8 patients at coronary bypass surgery. Intraluminal views were obtained by coupling the angioscope to a color video camera and videotape recorder, and compared with preoperative coronary angiographic findings in right and left anterior oblique views. Atherosclerotic plaque was observed as yellow-white mass attached onto the luminal lining, which may be large enough to virtually obliterate the vascular lumen. Angioscopy provided a topographic view and cross-sectional picture of stenosis not observed by angiography. Single-plane angioscopic cross-sectional stenotic lumens correlated well (r = 0.90, p less than 0.001) with calculated angiographic luminal narrowings. However, with subtotal obstruction, lesion length must be assessed angiographically. Coronary angioscopy can be a useful adjunct to angiography by providing the added dimension of the true cross-sectional view of obstruction.
Collapse
|
43
|
Abstract
Dipyridamole has been proposed as an ideal agent to evaluate coronary vascular reserve because it produces selective coronary vasodilation without systemic hemodynamic effect. The actions of intracoronary (IC) and intravenous (IV) dipyridamole on coronary blood flow and systemic hemodynamics were compared in 15 patients with chest pain syndrome and normal coronary arteries. They received IC dipyridamole, followed 10 minutes later by 0.5 mg/kg of IV dipyridamole. IC dipyridamole produced a 73% increase in coronary sinus flow without hemodynamic changes, except for a slight increase in pulmonary systolic and diastolic pressures. IV dipyridamole administration produced an additional 88% increase in coronary sinus flow, reaching 172% over baseline; it was also associated with a significant (p less than 0.01) increase in heart rate (78 +/- 14 vs 102 +/- 19 beats/min), cardiac index (4 +/- 0.7 vs 6.3 +/- 1.7 liters/min/m2), and pulmonary artery systolic (27 +/- 5 vs 34 +/- 7 mm Hg) and diastolic pressures (12 +/- 4 vs 19 +/- 7 mm Hg). These data suggest that the coronary vasodilatory effect seen after IV dipyridamole administration is related to mechanisms other than direct coronary vasodilation.
Collapse
|
44
|
Marchant E, Pichard A, Alcaino M, Corbalan R, Rodríguez JA, Morán S, Casanegra P. [Thrombolysis with intracoronary streptokinase in 11 patients with acute myocardial infarction]. Rev Med Chil 1985; 113:317-23. [PMID: 3835640] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
|
45
|
Goldbaum TS, Jacob AS, Smith DF, Pichard A, Lindsay J. Cardiac tamponade following percutaneous transluminal coronary angioplasty: four case reports. Cathet Cardiovasc Diagn 1985; 11:413-6. [PMID: 2931179 DOI: 10.1002/ccd.1810110410] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
Percutaneous transluminal coronary angioplasty (PTCA) has had complications related to dilating catheters and guide wires such as coronary artery dissection, spasm, rupture, and perforation. This report describes four patients who developed cardiac tamponade following PTCA, presumably from right ventricular (RV) perforation. All four received large doses of heparin during PTCA and three received antiplatelet therapy. In three cases, cardiac tamponade occurred several hours after PTCA. All patients did well following operative intervention and no patient required repair of a cardiac perforation. We postulate that impaired hemostasis in the presence of an otherwise inconsequential RV perforation causes tamponade. Three alternatives to provide standby pacing are proposed.
Collapse
|
46
|
Marchant E, Pichard A. [Relation between the clinical picture and the anatomical distribution and severity of stenotic lesions in coronary arteriosclerosis]. Rev Med Chil 1984; 112:1124-9. [PMID: 6537007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
|
47
|
Marchant E, Pichard A. [Topographic distribution of stenotic lesions of coronary arteriosclerosis. Angiographic study of 500 patients]. Rev Med Chil 1984; 112:434-40. [PMID: 6505434] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
|
48
|
Marchant E, Pichard A, Casanegra P, Rodríguez JA, Chamorro G, Corbalán R. [Coronary circulation in patients with left ventricular hypertrophy]. Rev Med Chil 1984; 112:447-56. [PMID: 6239343] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
|
49
|
Klein LW, Ambrose J, Pichard A, Holt J, Gorlin R, Teichholz LE. Acute coronary hemodynamic response to cigarette smoking in patients with coronary artery disease. J Am Coll Cardiol 1984; 3:879-86. [PMID: 6707354 DOI: 10.1016/s0735-1097(84)80344-7] [Citation(s) in RCA: 74] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
Abstract
The acute changes in coronary blood flow and coronary resistance that occur in response to cigarette smoking have not been accurately determined. To define the factors that affect this response, coronary sinus blood flow was measured in 16 patients (group I) with coronary artery disease and in 6 patients (group II) without angiographically detectable coronary disease. Seven patients (group IA) had severe (greater than or equal to 75%) proximal left coronary lesions and nine patients (group IB) had significant distal lesions with 50% or less proximal stenoses. Group I had a smaller overall increase (increases 1.6 +/- 5.3%) in coronary sinus blood flow than did group II (increases 7.7 +/- 6.1%) (p less than 0.05). Coronary resistance increased overall (increases 2.7 +/- 5.3%) in group I but decreased (decreases 2.4 +/- 3.4%) in group II (p less than 0.05). Patients in group IA had a highly significant increase in coronary resistance as compared with group IB (increases 7.0 +/- 4.2% versus decreases 0.9 +/- 2.6%) (p less than 0.001). Coronary sinus flow tended to decrease (decreases 1.2 +/- 4.6%) in group IA but to increase (increases 3.8 +/- 5.1%) in group IB (p = 0.06). It is concluded that smoking increases coronary resistance in patients with coronary artery disease. A greater impact is observed in patients with a severe proximal stenosis than in those with a distal stenosis. It is proposed that smoking increases coronary artery tone at the site of the stenosis, limiting the coronary flow response proportionally to the size of the affected vascular bed.
Collapse
|
50
|
Marchant E, Pichard A, Casanegra P. [Coronary steal with the use of dipyridamole in patients with obstructive coronary disease]. Rev Med Chil 1984; 112:342-9. [PMID: 6484360] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
|